An Open Label, Safety Study to Assess the Potential for Adrenal Suppression

Completed · Phase 2

Conditions studied: Plaque Psoriasis

In brief

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis

Key facts

Study ID

NCT02932878

Run by

Sun Pharmaceutical Industries, Inc.

People needed

16

Starts

2016-09-02

Expected to finish

2017-10-16

Last updated by the study team

2018-12-06

Who can join

Age: 2 and older, up to 18. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or non pregnant, non lactating females

You may not qualify if…

• Patients under 2 years of age

Where it is running

• Taro Pharmaceuticals USA Inc. — Hawthorne, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.